Loading
A phase 2 trial of Disitamab vedotin, Zimberelimab in cervical cancer, run by RemeGen Co., Ltd., now recruiting.
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06155396 by RemeGen Co., Ltd., with 116 participants planned, started 2024-01-11 and due to reach its primary completion in 2027-06-30. Interventions recorded: Disitamab Vedotin, Zimberelimab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zimberelimab, Recurrent or metastatic cervical cancer, Cervical cancer, Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC).
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/